Goserelin Combined With Bicalutamide Improves Immune Function And Inflammatory Response In Patients With Advanced Prostate Cancer

This study aimed to investigate the effect of goserelin combined with bicalutamide on the immune function and inflammatory response in advanced prostate cancer patients. From January 2017 to January 2019, 122 prostate cancer patients were selected as the research participants. Among them, 54 receiving intermittent therapy with goserelin and bicalutamide were included in group A, and 68 receiving continuous treatment with goserelin and bicalutamide were included in group B. The effects of the two treatment methods on the patients' clinical efficacy, safety, pain, immune function, and inflammatory factors were analyzed. The VAS scores of those in group A at 1 month, 6 months, and 12 months after they started taking the medication were significantly lower than those in group B (P<0.001). The CD4(+)CD8(+) levels of those in group A were significantly lower than those in group B at 6 months and 12 months after they started taking the medication (P<0.001). The CD4(+), CD8(+) and CD3(+) levels in group A at 6 months and 12 months after they started taking the medication were significantly higher than those in group B (P<0.001). The TNF-alpha, IL-1 beta, and IL-6 levels of those in group A treated for 6 months and 12 months were significantly lower than the corresponding levels in group B (P<0.001). There was no significant difference in the PSA and F-PSA levels between those in group A treated for 1 month, 6 months, and 12 months (P>0.05). There was no significant difference in the incidence of gynecomastia, breast tenderness, diarrhea, nausea, temporary liver function changes, kidney stones, osteoporosis, anemia, or other adverse reactions in either group (P>0.05). The total effective rate of group A was 94.44%, and the total effective rate of group B was 70.59%. The total effective rate of group A was significantly higher than the rate of group B (P<0.05). Goserelin combined with bicalutamide improves the clinical efficacy of intermittent therapy for advanced prostate cancer patients, increases their immune function, and relieves the body's inflammatory response.